Literature DB >> 9253417

Structural studies of poliovirus mutants that overcome receptor defects.

M W Wien1, S Curry, D J Filman, J M Hogle.   

Abstract

In order to better understand the process of cell entry for non-enveloped viruses, we have solved the crystal structures of five poliovirus mutants which can infect cells expressing mutant poliovirus receptors. Four of these structures have been solved from frozen crystals using cryocrystallographic data collection methods. The mutations have a range of structural consequences, from small local perturbations to significant loop rearrangements. All of the mutant viruses are more labile to conversion to an apparent cell entry intermediate, suggesting that these mutant viruses could compensate for the suboptimal receptors by lowering the thermal energy required to undergo the receptor-mediated conformational change.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9253417     DOI: 10.1038/nsb0897-666

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  22 in total

1.  Molecular tectonic model of virus structural transitions: the putative cell entry states of poliovirus.

Authors:  D M Belnap; D J Filman; B L Trus; N Cheng; F P Booy; J F Conway; S Curry; C N Hiremath; S K Tsang; A C Steven; J M Hogle
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 2.  Poliovirus cell entry: common structural themes in viral cell entry pathways.

Authors:  James M Hogle
Journal:  Annu Rev Microbiol       Date:  2002-01-30       Impact factor: 15.500

3.  Role of interfacial amino acid residues in assembly, stability, and conformation of a spherical virus capsid.

Authors:  Juan Reguera; Aura Carreira; Laura Riolobos; José María Almendral; Mauricio G Mateu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

4.  Detection of unusual mutation within the VP1 region of different re-isolates of poliovirus Sabin vaccine.

Authors:  Evaggelos Dedepsidis; Ioannis Karakasiliotis; Eleni Paximadi; Zaharoula Kyriakopoulou; Dimitrios Komiotis; Panayotis Markoulatos
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

5.  Retrospective characterization of a vaccine-derived poliovirus type 1 isolate from sewage in Greece.

Authors:  Evaggelos Dedepsidis; Zaharoula Kyriakopoulou; Vaia Pliaka; Christine Kottaridi; Eugenia Bolanaki; Stamatina Levidiotou-Stefanou; Dimitri Komiotis; Panayotis Markoulatos
Journal:  Appl Environ Microbiol       Date:  2007-09-07       Impact factor: 4.792

6.  An externalized polypeptide partitions between two distinct sites on genome-released poliovirus particles.

Authors:  Jun Lin; Naiqian Cheng; Marie Chow; David J Filman; Alasdair C Steven; James M Hogle; David M Belnap
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

7.  Nectin-like interactions between poliovirus and its receptor trigger conformational changes associated with cell entry.

Authors:  Mike Strauss; David J Filman; David M Belnap; Naiqian Cheng; Roane T Noel; James M Hogle
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

8.  Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.

Authors:  Zhaochun Chen; Konstantin Chumakov; Eugenia Dragunsky; Diana Kouiavskaia; Michelle Makiya; Alexander Neverov; Gennady Rezapkin; Andrew Sebrell; Robert Purcell
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

9.  Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes.

Authors:  Z Che; N H Olson; D Leippe; W M Lee; A G Mosser; R R Rueckert; T S Baker; T J Smith
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

10.  Cryo-electron Microscopy Structures of Expanded Poliovirus with VHHs Sample the Conformational Repertoire of the Expanded State.

Authors:  Mike Strauss; Lise Schotte; Krishanthi S Karunatilaka; David J Filman; James M Hogle
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.